Subscribe To
Lilly's (lly) ulcerative colitis candidate gets crl from fda
The FDA rejects Eli Lilly's (LLY) regulatory filing seeking approval for mirikizumab to treat ulcerative colitis indication, citing issues related to ...
April 14, 2023, 12:55 pm
Walgreens (wba) declares partnership with prothena corporation
Walgreens (WBA) collaborates with Prothena Corporation to support patient awareness, participation and representation in a clinical trial of Prothena'...
April 14, 2023, 9:07 am
Kala up on fast track designation to lead ocular candidate
KALA gets Fast Track Designation from the FDA for lead candidate KPI-012 to treat persistent corneal ep...
April 13, 2023, 12:56 pm
These up-and-coming stocks are screaming buys right now
Axsome launched its first products last year -- and others may be on the horizon. CRISPR recently completed regulatory submissions for a blood disorde...
April 13, 2023, 5:30 am
Structure therapeutics: developing innovative treatments for metabolic and fibrotic diseases
Structure Therapeutics has a promising pipeline of product candidates, including GSBR-1290, a GLP-1R ag...
April 12, 2023, 4:31 pm
Maia biotechnology (maia) up on positive data from nsclc study
MAIA Biotechnology (MAIA) gains on encouraging data on lead candidate from Part A of its mid-stage stud...
April 12, 2023, 3:57 pm
Moderna (mrna) posts 2027 biz view, down 3% on flu jab setback
Moderna (MRNA) expects $8-$15 billion in product revenues from the respiratory vaccine by 2027. Its first influenza vaccine ...
April 12, 2023, 12:55 pm
Merck shares fall after us fda halts new patient enrollment of ms drug candidate trials
The US Food and Drug Administration has hit pause on patient enrollment for German drugmaker Merck's multiple sclerosis drug ...
April 12, 2023, 9:38 am
Could this move make vertex's next blockbuster even bigger?
Vertex Pharmaceuticals recently completed regulatory requests for its blood disorder candidate, exa-cel...
April 12, 2023, 5:30 am
Moderna is developing a vaccine candidate against lyme disease that would be its first bacterial vaccine
Moderna Inc. MRNA, +1.19% outlined its clinical goals for its mRNA platform on Tuesday to mark its 4th Vaccine Day, including a new development ...
April 11, 2023, 7:27 am
Burberry's valuation and new strategy make it a potential takeover candidate
Burberry's strategy had strayed into the risky area of fast moving fashion; now it is going back to its more classic heritage styles. The new manageme...
April 11, 2023, 2:37 am
Moderna (mrna), merck's cancer jab gets ema's prime tag
The EMA grants PRIME designation to Moderna's (MRNA) personalized cancer vaccine candidate combined wit...
April 10, 2023, 12:56 pm
Zymeworks: exciting short squeeze candidate with large cash holdings
Zymeworks has an enterprise value approaching zero, as milestone drug development payments were paid to the company in 2022. A significant pipeline, w...
April 10, 2023, 1:17 am
Immunic's (imux) ulcerative colitis study shows positive data
Immunic (IMUX) reports positive results from the maintenance phase of the phase II study evaluating its lead c...
April 6, 2023, 3:14 pm
Vbi vaccines (vbiv) down 53% on initiating restructuring plans
VBI Vaccines (VBIV) will focus on its HBV vaccine product and advancing its HBV immunotherapeutic candid...
April 5, 2023, 12:56 pm
Vertex is 1 step closer to bringing a new blockbuster to market. time to buy?
Vertex Pharmaceuticals is a top seller of cystic fibrosis treatments -- but it's about to expand into a new growth area. Vertex and partner CRISPR The...
April 4, 2023, 2:00 pm
Interpublic group of companies: a value-investor candidate for total return
IPG's current yield of 3.5% is attractive for investors looking for a company that has a history of paying a growing dividend. IPG is trading at an at...
April 3, 2023, 7:23 pm
Why ascendis pharma stock is plunging today
The FDA has identified deficiencies in Ascendis' regulatory filing for the hypoparathyroidism candidate...
April 3, 2023, 12:28 pm
Could this move by johnson & johnson equal billions for moderna?
J&J is dropping out of the adult RSV vaccine race. This leaves the market to Moderna, Pfizer, and GSK; all three are close to reaching commercializati...
April 2, 2023, 5:30 am
Aridis provides corporate update
LOS GATOS, Calif., March 31, 2023 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceu...
March 31, 2023, 11:00 pm